EUVIMEDEUVIMED entdecken
Open Access

Inhaled toxicants and pulmonary lipid metabolism: biological consequences and therapeutic interventions

Hannah B Lovins, Brooke E Bathon, Saame Raza Shaikh, Kymberly M Gowdy

Toxicological Sciences · 2023

DOI: 10.1093/toxsci/kfad100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicological Sciences, 2023. Verfasst von Hannah B Lovins und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care and Sleep Medicine, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Pneumonia, Lung Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, Wiley Companies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhaled toxicants drive the onset of and exacerbate preexisting chronic pulmonary diseases, however, the biological mechanisms by which this occurs are largely unknown. Exposure to inhaled toxicants, both environmental and occupational, drives pulmonary inflammation and injury. Upon activation of the inflammatory response, polyunsaturated fatty acids (PUFAs) are metabolized into predominately proinflammatory lipid mediators termed eicosanoids which recruit immune cells to the site of injury, perpetuating inflammation to clear the exposed toxicants. Following inflammation, lipid mediator class-switching occurs, a process that leads to increased metabolism of hydroxylated derivates of PUFAs. These mediators, which include mono-hydroxylated PUFA derivatives and specialized proresolving lipid mediators, initiate an active process of inflammation resolution by inhibiting the inflammatory response and activating resolution pathways to return the tissue to homeostasis. Exposure to inhaled toxicants leads to alterations in the synthesis of these proinflammatory and proresolving lipid mediator pathways, resulting in greater pulmonary inflammation and injury, and increasing the risk for the onset of chronic lung diseases. Recent studies have begun utilizing supplementation of PUFAs and their metabolites as potential therapeutics for toxicant-induced pulmonary inflammation and injury. Here we will review the current understanding of the lipid mediators in pulmonary inflammation and resolution as well as the impact of dietary fatty acid supplementation on lipid mediator-driven inflammation following air pollution exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PneumoniaLung DiseasesHumansLipid MetabolismLungInflammationFatty Acids, UnsaturatedEicosanoidsInflammation Mediators

Stichwörter der Autor:innen

dietary supplementationinflammationlipid metabolismlungozoneparticulate mattersilica dustspecialized proresolving mediatortoxicology

Substanzen

Fatty Acids, UnsaturatedEicosanoidsInflammation Mediators

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care and Sleep Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Department of Nutrition, Gillings School of Global Public Health and School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Förderung

  • NIEHS NIH HHS
  • Wiley Companies

Zitieren

APA

Lovins, H. B., Bathon, B. E., Shaikh, S. R., & Gowdy, K. M. (2023). Inhaled toxicants and pulmonary lipid metabolism: biological consequences and therapeutic interventions. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfad100

Vancouver

Lovins HB, Bathon BE, Shaikh SR, Gowdy KM. Inhaled toxicants and pulmonary lipid metabolism: biological consequences and therapeutic interventions. Toxicological Sciences. 2023. doi:10.1093/toxsci/kfad100

BibTeX
@article{Lovins2023,
  author = {Lovins, Hannah B and Bathon, Brooke E and Shaikh, Saame Raza and Gowdy, Kymberly M},
  title = {Inhaled toxicants and pulmonary lipid metabolism: biological consequences and therapeutic interventions},
  journal = {Toxicological Sciences},
  year = {2023},
  doi = {10.1093/toxsci/kfad100}
}
Kostenlos starten →